title: Concomitant use of clopidogrel and proton pump inhibitors or cimetidine after acute myocardial infarction would increase the risk of re-infarction.
authors: Sophie
authors: S
authors: Sheng-Wen Wang
authors: Shang-Shyue
authors: SS
authors: Tsai
authors: Po-Chao
authors: PC
authors: Hsu
authors: Chun-Yuh
authors: CY
authors: Yang
authors: Deng-Chyang
authors: DC
authors: Wu
mesh_terms: D000483:Alleles; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D002927:Cimetidine / Q000009:adverse effects / Q000627:therapeutic use*; D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000235:genetics / Q000517:prevention & control*; D016017:Odds Ratio; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D054328:Proton Pump Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D013624:Taiwan; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000897:Anti-Ulcer Agents; D010975:Platelet Aggregation Inhibitors; D054328:Proton Pump Inhibitors; D002927:Cimetidine; D000077144:Clopidogrel; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D013988:Ticlopidine